logo

Calliditas Therapeutics Ab (Publ) (CALT)



Trade CALT now with
  Date
  Headline
5/19/2022 8:46:19 AM Calliditas Therapeutics's Kinpeygo Receives Positive CHMP Opinion In IgA Nephropathy
5/18/2022 1:33:32 AM Calliditas Therapeutics Reports Q1 Net Sales Of SEK 49.7 Mln; Loss/shr Of SEK 2.62
3/13/2022 9:12:26 PM Everest Medicines Reaches Deal With Calliditas , Expanding Territory License To Commercialize NEFECON In South Korea
2/15/2022 4:47:43 AM Calliditas Therapeutics Says First Patient Randomized In Pivotal TRANSFORM Study With Setanaxib
1/28/2022 2:17:36 AM Calliditas Therapeutics Announces Commercial Availability And Initial Sales Of TARPEYO
11/18/2021 1:25:29 AM Calliditas Therapeutics Q3 Operating Profit SEK 7.9 Mln Vs. Operating Loss SEK 104.9 Mln Prior Year
8/19/2021 1:27:50 AM Calliditas Therapeutics Q2 Loss/shr SEK 3.20 Vs. Loss/shr SEK 1.50 Prior Year
8/9/2021 3:19:43 AM Calliditas: FDA Grants Fast Track Designation For Setanaxib In Primary Biliary Cholangitis
7/21/2021 3:09:38 AM Calliditas Therapeutics And STADA Partner To Commercialize Specialty Therapy For IgA Nephropathy In Europe
7/15/2021 3:05:08 AM Calliditas Therapeutics Signs Loan Agreement Of Up To The Euro Equivalent Of $75 Mln With Kreos Capital
5/28/2021 9:09:01 AM Calliditas Submits Marketing Authorisation Application For Nefecon To The European Medicines Agency
5/18/2021 1:16:33 AM Calliditas Therapeutics Q1 Loss Per Share SEK 2.51 Vs Loss SEK 1.65 Last Year